Control Bionics Ltd (cbl) Logo

Control Bionics Ltd (CBL)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

CBL Chart

Snapshot

CBL's Principal Activity is the development, commercialisation and sale of assistive communications technology systems within the disability sector.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -72.62%

Size

Market Capitalisation
ASX Rank 1,606 of 2,319
Sector Rank 149 of 198

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies BDA / IMC / TRU
EPS -$0.057
DPS $0.00
NTA per share $0.00

Broker Consensus

CBL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Control Bionics Limited (CBL) designs, manufactures and sells wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. This allows users to operate and communicate via a computer using intentional thought and the body's own neuroelectric signals detected at skeletal muscle sites - the physical movement of a muscle is not necessary for the technology to detect and interface.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Surrey Hills VIC 3127
Website www.controlbionics.com
Registry Automic Group
Auditor BDO Audit Pty Ltd
Date Listed 7 Dec 2020

Upcoming Calendar (Forecasted)

Date Event
24/02/2022 Report (Interim)
25/08/2022 Report (Prelim)
25/08/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
08/09/2017 $0.0135 0% $0.0135 Interim 21/09/2017
13/03/2017 $0.0183 0% $0.0183 Final 31/03/2017
27/10/2016 $0.0283 0% $0.0283 Interim 04/11/2016
14/04/2016 $0.0404 0% $0.0404 Final 22/04/2016

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.00
Gross DPS(TTM) $0.00
Dividend yield
Gross yield
Payout Ratio --
DRP No
DRP Features -

Directors & Management

Directors & Management

Name Title Since Bio
Mr Damian Lismore Non-Executive Director Sep 2020 Director Bio icon

Mr Damian Lismore

Non-Executive Director

Mr Lismore has commercial, international and listed company experience (both ASX and NASDAQ), covering many industries including healthcare and technology. In his executive career, he held CEO, CFO and Company Secretarial roles and continues to act as an advisor to CEOs, boards and business owners. Damian is currently CFO of Scout Bio Inc, a Frazier Healthcare Partners backed company. He is Chair of the Risk committee.

Mr Robert William Wong Chief Executive Officer,Managing Director Sep 2020 Director Bio icon

Mr Robert William Wong

Chief Executive Officer,Managing Director

Mr Wong has over 25 years of experience with multinational businesses in senior management, marketing, and operational roles. He is also an entrepreneur and angel investor having been involved with several technology start-up businesses. He formerly held the position of CEO at AIMIA Digital Industry Association of Australia. Rob joined Control Bionics in early 2017 and he has led the way in developing the latest product, the NeuroNode Trilogy. Rob has spent much of his time with Control Bionics presenting to industry leaders, forming research and development relations, and working hands-on with clients across the world. He is a member of the Risk committee.

Mr Roger David Hawke Non-Executive Chairman,Non-Executive Director Sep 2018 Director Bio icon

Mr Roger David Hawke

Non-Executive Chairman,Non-Executive Director

Mr Hawke has over 30 years of experience in the telecommunications and technology space, having retired after 8 years as CEO & Managing Director of Crown Castle Australia/Axicom, and brings experience particularly in Technology, Operations, Sales and Management. He is a member of the Risk Management committee.

Mr Lindsay John Phillips Non-Executive Director Aug 2014 Director Bio icon

Mr Lindsay John Phillips

Non-Executive Director

Mr Phillips is an experienced private equity fund Managing Director and Chairman. Lindsay first invested in Control Bionics in 2005. Lindsay was Managing Director of Lazard Australia Private Equity from 2007 to 2012. Since 2012 Lindsay has been Chairman of Phoenix Development Fund and Nightingale Partners. He is a member of the Risk committee.

Mr Peter Shann Ford Executive Director Jul 2005 Director Bio icon

Mr Peter Shann Ford

Executive Director

Mr Ford is the Founder and Director of Innovation at Control Bionics Limited. After spending three years as a founding programmer at the US Veterans Administration Medical Center Rehabilitation R&D Laboratory in Atlanta - one of the first of its kind in the USA - while a news anchor at CNN and CNN2, Peter began consulting to therapists and disability clients in innovative Assistive Technology, including bionics and robotics. From 2002-2007 he Beta-tested evolving prototypes of his coding with Prof Hawking at Texas A&M University and Cambridge University, and with doctors and their patients and clients in the USA, Australia and New Zealand. In 2005, with an initial investment from Phoenix Development Fund in Australia, Control Bionics was born. He is a member of the Risk committee.

Mr Brett Thomas Crowley Company Secretary N/A
Mr Neale Java Chief Financial Officer N/A

Director Transactions

CBL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
27/09/21 Lindsay Phillips Buy +18,000 $0.659 $11,861 On-market trade
22/09/21 Lindsay Phillips Buy +51,037 $0.654 $33,378 On-market trade
20/09/21 Lindsay Phillips Buy +71,991 $0.648 $46,619 On-market trade
18/03/21 Damian Lismore Buy +25,000 $0.61 $15,250 On-market trade

Director Interests

The current holdings of CBL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Lindsay Phillips 27/09/2021 N/A 17,336,704 N/A N/A
Peter Ford 30/06/2021 21,258,313 N/A 3,567,860 N/A
Robert Wong 30/06/2021 N/A 2,540,616 3,365,678 N/A
Roger Hawke 30/06/2021 N/A 758,478 N/A N/A
Damian Lismore 30/06/2021 N/A 55,000 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 11, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Peter Shann Ford 21,258,313 25.45%
Nightingale Partners Pty Limited 9,117,123 10.91%
Phoenix Development Fund Limited 8,019,581 9.60%
Bnp Paribas Noms Pty Ltd <Drp> 4,488,696 5.37%
Loidl Nominees Pty Ltd <Loidl Family A/C> 2,541,289 3.04%
R & R Wong Holdings Pty Limited <R & R Wong Family Super A/C> 2,540,616 3.04%
Pacific Atlantic Commerce Pty Ltd <Corcillum Super Fund A/C> 1,396,182 1.67%
Dowe Holdings Pty Limited 1,121,893 1.34%
Windward Capital Pty Ltd <S&L Rix Superfund A/C> 1,118,863 1.34%
Brindle Holdings Pty Ltd <O Connor S/F A/C> 1,100,000 1.32%
Santios Pty Limited <The Mcmurray Family A/C> 999,219 1.20%
National Nominees Limited 845,311 1.01%
James Schorey 834,168 1.00%
Nandaroo Pty Limited 792,202 0.95%
Robert Allwell Pty Ltd <Robert Allwell Superfund A/C> 781,757 0.94%
Paula Darling 781,757 0.94%
Hafnium Management Pty Ltd <Hafnium Family A/C> 758,478 0.91%
Paul Mahon 701,183 0.84%
Darrell G Blandford 611,303 0.73%
Dianna Louise Cooke 575,307 0.69%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 441 530 376 40 1,387

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Nightingale Partners Pty Limited 11/08/2021 9,117,123 10.94
BNP Paribas Noms Pty Ltd 11/08/2021 4,488,696 5.37
Phoenix Development Fund Limited 11/08/2021 8,019,581 9.60
Peter Shann Ford 11/08/2021 21,258,313 25.51

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
05-03-21 Acorn Capital Limited 4,422,182 -- 5.27
07-12-20 Phoenix Development Fund Limited 8,019,581 -- 9.62
07-12-20 Nightingale Partners Pty Limited 9,117,123 -- 10.94
07-12-20 Peter Shann Ford 21,258,313 -- 25.51

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
CBL Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.